COVID-19 Associated Vasculitis Confirmed by the Tissues RT-PCR: A Case Series Report
Authors:
- Konstantin E. BelozerovKBKonstantin E. Belozerov
- Ilia S. AvrusinIAIlia S. Avrusin
- Lyubov I. AndaryanovaLALyubov I. Andaryanova
- Anna M. GusevaAGAnna M. Guseva
- Zaira S. ShogenovaZSZaira S. Shogenova
- Irina N. BelanovichIBIrina N. Belanovich
- Anna V. LobachevaALAnna V. Lobacheva
- Tatiana L. KornishinaTKTatiana L. Kornishina
- Eugenia A. IsupovaEIEugenia A. Isupova
- Vera V. MasalovaVMVera V. Masalova
- Olga V. KalashnikovaOKOlga V. Kalashnikova
- Andrey V. NokhrinANAndrey V. Nokhrin
Open Access
- 13 March 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (3) , 870
Abstract
Background: Several cases of skin and central nervous system vasculopathy associated with COVID-19 in children have been published, but the information is rather limited. Our study aimed to describe these cases of vasculitis associated with COVID-19 in children. Methods: In the retrospective-prospective case series study we included information regarding four children with COVID-19-associated vasculitis. In every case, we had a morphological description and the etiology was confirmed via real-time polymerase chain reaction during a tissue biopsy. Results: The most involved systems were skin (4/4), respiratory (3/4), cardiovascular (2/4), nervous (1/4), eye (1/4), kidney (1/4), and inner year (1/4). All patients had increased inflammatory markers and thrombotic parameters (D-dimer). No patient met the criteria for multisystem inflammatory syndrome in children. Two patients met polyarteritis nodosa criteria, one met Henoch–Schonlein purpura criteria, and one met unclassified vasculitis criteria. All patients were treated with systemic glucocorticosteroids (two-pulse therapy). Non-biologic DMARDs were prescribed in all cases; 1/4 patients (25%) was treated with intravenous immunoglobuline, and 3/4 (75%) were treated with biologics (etanercept, tocilizumab, and adalimumab). Conclusions: Vasculitis associated with COVID-19 could be a life-threatening condition; SARS-CoV-2 might be a new trigger or etiological agent for vasculitis and other immune-mediated diseases. Further research and collection of similar cases are required.Keywords
This publication has 24 references indexed in Scilit:
- Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance studyThe Lancet Psychiatry, 2020
- Chilblain-like acral lesions during the COVID-19 pandemic (“COVID toes”): Histologic, immunofluorescence, and immunohistochemical study of 17 casesJournal of the American Academy of Dermatology, 2020
- COVID-19-associated vasculitis and vasculopathyJournal of Thrombosis and Thrombolysis, 2020
- Severe COVID-19: NLRP3 Inflammasome DysregulatedFrontiers in Immunology, 2020
- Targeting the NLRP3 Inflammasome in Severe COVID-19Frontiers in Immunology, 2020
- SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric casesBritish Journal of Dermatology, 2020
- Coronavirus (COVID-19) infection–induced chilblains: A case report with histopathologic findingsJAAD Case Reports, 2020
- Prolonged SARS‐CoV‐2 RNA detection in anal/rectal swabs and stool specimens in COVID‐19 patients after negative conversion in nasopharyngeal RT‐PCR testJournal of Medical Virology, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- Hemodynamic regulation of perivalvular endothelial gene expression prevents deep venous thrombosisJournal of Clinical Investigation, 2019